Jim Cramer breaks down drug stocks amid concerns over Zantac litigation

CNBC Television published this video item, entitled “Jim Cramer breaks down drug stocks amid concerns over Zantac litigation” – below is their description.

‘Mad Money’ host Jim Cramer and the ‘Squawk on the Street’ team discuss pharma stocks that are trading lower amid alleged concerns that Sanofi and GSK’s antacid drug Zantac causes cancer.

CNBC Television YouTube Channel

Got a comment? Leave your thoughts in the comments section, below. Please note comments are moderated before publication.

About This Source - CNBC Television

CNBC is an American pay television business news channel, which primarily carries business day coverage of U.S. and international financial markets. Following the end of the business day and on non-trading days, CNBC primarily carries financial and business-themed documentaries and reality shows.

As of February 2015, CNBC is available to approximately 93,623,000 pay television households (80.4% of households with television) in the United States.

Recent from CNBC Television:

Pitcairn: October could be the month we see downward corporate earnings revisions

People in hardest hit areas of Florida beg for help

Russian missile destroys apartment block in Zaporizhzhia, as Ukraine continues to reclaim territory

In This Story: Jim Cramer

James Joseph Cramer is an American television personality and host of Mad Money on CNBC. He is a former hedge fund manager as well as an author and a co-founder of TheStreet.com. He was raised in Wyndmoor, Pennsylvania.

3 Recent Items: Jim Cramer

Jim Cramer on the ‘euphoria’ driving inflation higher

Cramer’s lightning round: GXO Logistics is a buy

Jim Cramer says economic data can’t capture one huge driver of inflation

In This Story: Sanofi

Sanofi S.A. is a French multinational pharmaceutical company headquartered in Paris, France, as of 2013 the world’s fifth-largest by prescription sales.

2 Recent Items: Sanofi

Drug stocks under pressure over Zantac litigation concerns

Regeneron to buy Sanofi’s cancer drug in $1B deal

Leave a Comment

We don't require your email address, or your name, for anyone to leave a comment. If you do add an email address, you may be notified if there are replies to your comment - we won't use it for any other purpose. Please make respectful comments, which add value, and avoid personal attacks on others. Links are not allowed in comments - 99% of spam comments, attempt to post links. Please describe where people may find additional information - for example "visit the UN website" or "search Google for..." rather than posting a link. Comments failing to adhere to these guidelines will not be published.